Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma (BRd)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Celgene Corporation
Mundipharma Research GmbH & Co KG
Mundipharma Medical Company
Amgen
Information provided by (Responsible Party):
PD Dr. Ulrich Mey, Kantonsspital Graubünden
ClinicalTrials.gov Identifier:
NCT01701076
First received: September 27, 2012
Last updated: June 11, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2017
  Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)